Viatris Inc 8-K, filed May 5, 2025
Viatris Inc (VTRS)
8-K
2025-05-05
For: 2025-05-05
View Original
Added on
April 10, 2026
About this 8-K
Viatris Inc filed this 8-K on May 5, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (724 ) 514-1800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Director Appointments
On May 5, 2025, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board
from 12 to 14 and appointed Frank D’Amelio and Michael Severino as independent (as defined in the applicable NASDAQ listing rules) members of the Board, effective immediately, with terms of office expiring at the Company’s 2025 annual meeting of
shareholders (the “2025 Annual Meeting”). The Board appointed Mr. D’Amelio to the Finance Committee of the Board and Dr. Severino to the Science and Technology Committee of the Board, each appointment effective May 5, 2025. Mr. D’Amelio and Dr.
Severino will each receive compensation for his role as an independent member of the Board consistent with the compensation of the Company’s other non-employee directors as disclosed in the Amendment to Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2024. The Company has entered into an indemnification agreement with each of Mr. D’Amelio and Dr. Severino, the form of which appears as Exhibit 10.25 to the Company’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2020.
There are no arrangements or understandings between each of Mr. D’Amelio and Dr. Severino and any other persons pursuant to which he
was selected as a director and Mr. D’Amelio and Dr. Severino each has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Director Retirements
On May 5, 2025, Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025
Annual Meeting and to retire as a member of the Board at the end of his current term, which is scheduled to expire at the 2025 Annual Meeting. Neither director’s retirement was the result of any disagreement between such director and the Company on
any matter relating to the Company’s operations, policies, or practices.
|
Item 7.01
|
Regulation FD Disclosure.
|
On May 5, 2025, the Company issued a press release announcing the appointments of Mr. D’Amelio and Dr. Severino to the Board and the retirements of Mr.
Malik and Mr. Korman from the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
Press release announcing the appointments of Mr. D’Amelio and Dr. Severino to the Viatris Board of Directors and the retirements of Mr. Malik and Mr. Korman from
the Viatris Board of Directors, dated May 5, 2025.
|
|
|
104
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
VIATRIS INC.
|
||
| Date: May 5, 2025 | By: |
/s/ Theodora Mistras |
|
Theodora Mistras
|
||
|
Chief Financial Officer
|
||
Exhibit 99.1
Viatris Announces Appointments of Frank D’Amelio and Michael Severino, M.D., to the Company’s Board of Directors
Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms
PITTSBURGH – May 5, 2025 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Frank D’Amelio and Michael Severino, M.D., have been appointed as the newest members of
Viatris’ Board of Directors. In addition, the Company announced that current directors, Rajiv Malik and Harry (Hal) Korman, will retire from the Board at the end of their current terms in December following the Company’s 2025 Annual Meeting of
Shareholders.
D’Amelio is a well-respected pharmaceutical industry veteran with 20 years of experience as a public company CFO, most recently serving as Executive Vice President
& CFO at Pfizer. During his 15-year tenure as Pfizer CFO, he was responsible for all corporate finance functions, including audit, treasury, tax, investor relations, insurance, financial planning, corporate controllership, business finance
and analytics, as well as business operations, which included IT, procurement, real estate and business development. In addition, from 2018 to 2021, including during the height of the COVID-19 pandemic, he also served as Executive Vice President
of Global Supply.
Prior to his time at Pfizer, D’Amelio held various roles of increasing responsibility at Alcatel-Lucent, S.A. and its predecessor, Lucent Technologies, including as
Chief Operating Officer, Chief Financial Officer, and Chief Administrative Officer, as well as at AT&T, Inc. He currently serves on the Board of Directors of Humana Inc., Zoetis Inc., Hewlett Packard Enterprise Company, Sail Biomedicines,
Inc. and EntityRisk, Inc. In addition, he is a Strategic Advisor for Formation Bio. D’Amelio earned his MBA from St. John’s University and his bachelor’s degree in accounting from St. Peter’s University.
Severino is a highly experienced corporate executive and drug developer, currently serving as Chief Executive Officer of Tessera Therapeutics, Inc. and CEO-Partner of
Flagship Pioneering, positions he has held since 2022. Prior to that, he served as Vice Chairman and President of AbbVie Inc., as well as AbbVie’s Executive Vice President, Research & Development, and its Chief Scientific Officer. He also
spent 10 years at Amgen Inc., serving in a variety of leadership positions, including Senior Vice President, Global Development, and Chief Medical Officer.
Severino serves on the Board of Directors of Avantor, Inc., Montai Therapeutics, Inc., and Quotient Therapeutics, Inc. He earned an M.D. from Johns Hopkins University,
completing his residency and fellowship training at Massachusetts General Hospital and Harvard Medical School, as well as a bachelor’s degree in biochemistry from the University of Maryland.
Melina Higgins, Chair of Viatris’ Board of Directors said, “We are
extremely pleased to welcome Frank and Mike to the Viatris Board effective today. They each bring not only significant board experience, but deep pharmaceutical industry and executive experience across a variety of key disciplines that we
believe will serve the Board and the Company well. We look forward to their contributions as we continue our work to accelerate shareholder return and position Viatris for long-term growth.”
Higgins continued, “On behalf of the entire Board, we cannot thank Rajiv and Hal enough for their service and significant contributions to both Viatris and the Board.
Their long-standing commitment to the Company and its people has been truly impressive, and the significant value they have brought to the Board through their experience and dedication to collaboration has been sincerely appreciated.”
Scott A. Smith, Viatris’ Chief Executive Officer commented, “I could not be more excited by the additions of Frank and Mike to the Viatris Board. I believe Frank’s
well-known finance and operational expertise, and Mike’s extensive drug development and management background will prove extremely beneficial not only to the Board but to the executive management team. I look forward to working closely with them
and the entire Board to ensure we continue to execute on our vision for the Company.”
Added Smith, “I also want to express my sincere thanks to Rajiv and Hal for their incredible legacy of service to Viatris. Their partnership and knowledge sharing during our work to transition the Company for the
future has been invaluable.”
Malik stated,
“As I have long said, my time at Mylan and now Viatris has been nothing short of extraordinary. It has been a privilege to be a part of building such a one-of-a-kind company. Over the last two decades, we were able to significantly expand the
global scale of our commercial and operations footprint and establish a highly diverse scope of scientific capabilities.”
Malik continued,
“I will depart the Board with an immense sense of pride in all that has been accomplished, as well as in the strong foundation that has been set for the future, which should serve the Board and management team well as they now set course for
the Company’s next phase of achievements.”
Korman said,
“It has been an honor to have been able to serve on the Viatris Board. Since first joining Mylan and its management team almost 30 years ago, I have seen the Company grow from a company serving a single country to one serving approximately 1
billion patients around the world each year. It has been a remarkable transformation, and I am extremely proud to have played a part in this success.”
Added Korman, “I
am also highly gratified by the work we have been able to do as a Board over the last several years to establish a new vision for the Company that I believe should sustain it well into the future. I wish the Board, the management team, and all
involved at Viatris nothing but the best in the journey ahead.”
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more
holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around
the world annually and touching all of life’s moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach
more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh,
Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).
Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements.” These statements are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding Rajiv Malik and Hal Korman retiring from the Board at the end of their current
terms in December following the Company’s 2025 Annual Meeting of Shareholders; looking forward to their contributions as we continue our work to accelerate shareholder return and position Viatris for long-term growth; ensuring we continue to
execute on our vision for the Company; transitioning the Company for the future; the strong foundation that has been set for the future, which should serve the Board and management team well as they now set course for the Company’s next phase of
achievements; and establishing a new vision for the Company that I believe should sustain it well into the future. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply
with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris’ ability to bring new products to market; Viatris’ or its partners’
ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris’ failure to achieve expected or targeted future financial and
operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris’ or its partners’ customer and supplier relationships and customer purchasing patterns;
the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, tariffs
and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris’ filings with the Securities and Exchange Commission (“SEC”). Viatris routinely uses its website as a means of disclosing material
information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release
other than as required by law.
| Contacts: | ||
|
MEDIA
|
INVESTORS | |
|
+1.724.514.1968
|
+1.412.707.2866
|
|
|
Communications@viatris.com
|
InvestorRelations@viatris.com
|
|
|
Jennifer Mauer
|
Bill Szablewski
|
|
|
Jennifer.Mauer@viatris.com
|
William.Szablewski@viatris.com
|
|
|
Matt Klein
|
||
|
Matthew.Klein@viatris.com
|